TEOSYAL®'s primary clinical differentiator is RHA technology. The brand is best known for RHA, Resilient Hyaluronic Acid, a crosslinking technology designed for dynamic facial areas where filler flexibility and tissue movement are clinically critical. Looking to buy TEOSYAL® online? Licensed practitioners can contact the Med Supply Solutions team for guidance on availability, documentation, and account setup.
Filters
Category
Brand
Price Range
$
$
Most ordered from TEOSYAL®
Global Best Sellers
Why Healthcare Professionals Choose TEOSYAL®?
TEOSYAL® dermal fillers are a hyaluronic acid filler range developed by Teoxane, with two core product families: PURESENSE and RHA. Conventional HA crosslinking methods can fragment or overly modify the HA polymer network, producing a gel that resists rather than follows natural facial movement. RHA technology uses a gentler manufacturing process that preserves more of the native HA chain length, resulting in a resilient gel structure with tissue-like adaptability. This is clinically meaningful for high-mobility areas (e.g., the perioral region, glabella, forehead, and crow's feet) where a rigid filler creates visible stiffness or unnatural restriction of expression. The RHA1 to RHA4 range offers a graduated viscosity spectrum, allowing practitioners to match gel resilience and rheological properties to wrinkle depth, tissue mobility, and the degree of dynamic correction required. [4] The second differentiator is TEOSYAL®'s dual-line architecture. PURESENSE products address static lines, volume restoration, lips, under-eye correction, and skin-quality indications through a BDDE-crosslinked HA formulation with mannitol for oxidative stress reduction. RHA products address dynamic wrinkles and expression areas through the resilient gel mechanism described above. A practitioner working with both lines can build full-face HA protocols within a single brand, applying the appropriate technology to each anatomical zone and indication — reducing the need to source complementary products from multiple suppliers. [4]Order TEOSYAL® at Wholesale Prices
Med Supply Solutions offers TEOSYAL® products to licensed medical professionals at wholesale prices, with guaranteed delivery, verifiable LOT numbers, and fast shipping. Looking to buy TEOSYAL® online? Get in touch with the team at Med Supply Solutions for guidance on availability and account setup.The TEOSYAL® Product Range
The PURESENSE range includes products designed for different anatomical needs and injection depths. TEOSYAL® PURESENSE Redensity I supports skin hydration and tissue quality, while TEOSYAL® REDENSITY II is formulated for the under-eye area and tear trough correction. PURESENSE Kiss is indicated for lip shape, volume, and definition, while Global Action and Deep Lines address wrinkles and folds at appropriate dermal depths. Ultra Deep and Ultimate are used for deep volume restoration, cheek support, structural contouring, and facial projection. [4] The TEOSYAL® RHA Collection is the brand's strongest technical category. RHA1 is used for superficial dynamic lines; RHA2 and RHA3 support moderate-to-severe dynamic wrinkles and folds; RHA4 is positioned for deeper folds, facial contouring, and dynamic areas requiring more structural support. The clinical rationale for this range lies not simply in product variety but in the ability to match gel resilience and viscosity precisely to tissue movement and wrinkle depth — a distinction that matters most in high-mobility treatment zones. [4] Together, PURESENSE and RHA allow practitioners to build complete facial HA protocols covering hydration, lip enhancement, under-eye correction, facial folds, and dynamic expression areas. Product selection should be guided by tissue depth, tissue mobility, indication, and the desired correction behavior at each anatomical zone.TEOSYAL® Treatment Areas
TEOSYAL® addresses treatment areas across the face organized by product line and clinical objective. Lip protocols using PURESENSE Kiss or RHA Kiss target lip shape, border definition, and volume, with RHA Kiss providing added movement adaptability in a high-mobility area. Nasolabial folds and marionette lines are addressed by Global Action, Deep Lines, or RHA2/RHA3, depending on whether the primary etiology is static or dynamic. Cheeks and temples, where structural support and volumization are the clinical priorities, are typically treated with Ultra Deep, Ultimate, or RHA4. [4] TEOSYAL® REDENSITY II is formulated for the tear trough and periorbital region, where product selection, injection plane, and tissue visibility are particularly critical considerations. For dynamic expression areas — forehead lines, glabella, crow's feet, and perioral wrinkles driven by repeated muscle movement — RHA1 through RHA4 are the clinically appropriate options, selected for their capacity to adapt to facial expression while maintaining correction. TEOSYAL® PURESENSE Redensity I addresses skin hydration and quality through a skin-booster protocol applicable to the face, neck, and hands.About TEOSYAL®
TEOSYAL® is manufactured by Teoxane SA, an aesthetics company headquartered in Geneva, Switzerland, founded in 2003 with a core focus on hyaluronic acid science. TEOSYAL® is Teoxane's primary injectable filler brand. Teoxane manufactures and manages TEOSYAL® through its own brand and regional distribution partners, with availability varying by market. TEOSYAL® products are available in more than 90 countries globally. [4] Teoxane developed the PURESENSE range — formulated to include mannitol as an antioxidant component, intended by the manufacturer to help limit oxidative stress in the gel environment — before introducing RHA technology to address the clinical challenge of dynamic facial areas. RHA 2, RHA 3, and RHA 4 received FDA approval in 2017 as the first FDA-approved hyaluronic-based fillers specifically indicated for dynamic facial wrinkles and folds. Today, TEOSYAL® is positioned as a premium Swiss-made HA filler with particular clinical relevance in dynamic area treatment. Clinics comparing HA filler portfolios may also review the JUVÉDERM® collection for cross-brand product planning. [1][3]TEOSYAL® Safety Profile
TEOSYAL® safety considerations are consistent with injectable HA filler procedures. Common injection-site reactions may include redness, swelling, bruising, pain, tenderness, itching, firmness, or temporary discomfort. These reactions typically resolve within several days, although duration varies by product, treatment area, injection depth, and individual patient factors. The PURESENSE line is formulated to include mannitol as an antioxidant component, intended by the manufacturer to help limit oxidative stress in the gel environment — a formulation distinction from standard HA fillers. TEOSYAL® products should not be used in patients with known hypersensitivity to HA or any excipient, and use should be avoided in areas with active skin inflammation or infection. Safety has not been established in patients under 18, and caution is advised during pregnancy and breastfeeding. Because TEOSYAL® is HA-based, correction with hyaluronidase may be considered when clinically appropriate. [4]TEOSYAL® Regulatory Status
TEOSYAL® RHA2, RHA3, and RHA4 received FDA approval on October 19, 2017, under PMA P170002, for the correction of moderate-to-severe dynamic facial wrinkles and folds in adults aged 22 years or older. [1][2] The TEOSYAL® RHA Collection is recognized as the first FDA-approved hyaluronic-based filler line specifically indicated for dynamic facial wrinkles and folds. [1][3] TEOSYAL® PURESENSE products are available in international markets under CE Mark and applicable local regulatory pathways. Teoxane is ISO 13485 certified, and TEOSYAL® products carry CE marking across the European Union. Product names, labeling, and approved indications vary by jurisdiction — practitioners should verify local regulatory status and current product documentation before ordering or using TEOSYAL® products. [4]How Long Does TEOSYAL® Last?
TEOSYAL® results generally last 6–18 months, depending on the product, treatment area, injection technique, patient metabolism, and tissue movement. RHA products have published clinical study data supporting durability in dynamic facial areas, with results in study populations showing improvement over follow-up periods of up to 15 months for RHA2 and up to 18 months for RHA3 in appropriate clinical contexts. Areas with higher tissue mobility, such as the lips and perioral region, may require earlier maintenance than deeper contouring zones. [5]FAQs
1. How do TEOSYAL® PURESENSE and RHA® differ in formulation?
The main difference is how each line is designed to behave in tissue. PURESENSE products use BDDE-crosslinked hyaluronic acid with lidocaine and mannitol and are available for indications such as static wrinkles, lip enhancement, under-eye correction, skin quality, and facial volume. RHA® products are manufactured using a process intended to preserve more of the native HA chain structure, creating gels that can better accommodate repeated facial movement.2. Which facial areas are commonly treated with TEOSYAL® RHA?
The RHA® range is designed for regions where expression and tissue movement are important considerations. Depending on the specific product and approved indication, this can include dynamic wrinkles and folds around the forehead, glabella, lateral eye area, and perioral region. RHA2, RHA3, and RHA4 are FDA-approved for moderate-to-severe dynamic facial wrinkles and folds in adults aged 22 years and older.[1][2]3. What determines how long TEOSYAL® results may last?
Longevity varies according to the formulation selected, treatment location, tissue mobility, patient metabolism, and injection technique. Across the TEOSYAL® portfolio, results are commonly reported within an approximate 6- to 18-month range. Published studies have followed clinical improvement for up to 15 months with RHA2 and up to 18 months with RHA3 in studied treatment settings.[5]4. Which TEOSYAL® fillers have FDA authorization in the United States?
RHA2, RHA3, and RHA4 received FDA approval on October 19, 2017, under PMA P170002 for correction of moderate-to-severe dynamic facial wrinkles and folds in adults aged 22 years or older.[1] Other TEOSYAL® products, including many PURESENSE formulations, are marketed internationally under CE marking and other country-specific regulatory pathways rather than the same US approval.5. Why is TEOSYAL® REDENSITY II associated with the under-eye area?
REDENSITY II was developed specifically for the periorbital region, including tear trough correction. Because the skin and soft tissue around the eyes are thin and highly visible, treatment in this area requires careful product selection, precise placement, and close attention to anatomy.6. Can unwanted TEOSYAL® filler be dissolved?
Because TEOSYAL® fillers are based on hyaluronic acid, hyaluronidase may be used to break down the material when reversal is clinically indicated. Decisions about dissolution should be made and carried out by a practitioner experienced in managing HA fillers and related complications.7. What should practitioners review before choosing a TEOSYAL® product?
Selection should be based on more than brand name alone. Relevant considerations include the treatment area, desired degree of projection or flexibility, tissue characteristics, product rheology, regulatory status, and the individual patient’s anatomy and treatment goals.8. How can licensed professionals source TEOSYAL® through Med Supply Solutions?
Licensed healthcare professionals interested in sourcing TEOSYAL® can contact Med Supply Solutions for information on product availability, required documentation, account verification, and procurement requirements. Practitioners should also confirm that the specific formulation they plan to purchase is authorized for use in their jurisdiction.Citations
- US Food and Drug Administration. Premarket approval (PMA): P170002. Published 2017.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170002
- US Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED), PMA P170002. October 19, 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170002B.pdf
- Mastering Movement with RHA® Technology. https://www.teoxane.com/en/rha-aesthetic-innovation-in-motion
- Teoxane Dermal Fillers and Dermocosmetics Solutions. https://www.teoxane.com/en/healthcarepractitioners/dermal-fillers-dermocosmetics-solutions
- Monheit G, Kaufman-Janette J, Joseph JH, Shamban A, Dover JS, Smith S. Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds: A 64-Week, Prospective, Multicenter, Controlled, Randomized, Double-Blinded, and Within-Subject Study. Dermatol Surg. 2020;46(12):1521-1529. doi:10.1097/DSS.0000000000002391
Newsletter
Subscribe for exclusive offers and updates on new arrivals
- item.id === nextId);
if(existingIndex !== -1){
toasts.splice(existingIndex, 1);
}
toasts.unshift({
id: nextId,
show: false,
message: event.detail.message,
description: event.detail.description,
type: event.detail.type,
html: event.detail.html,
duration: Number(event.detail.duration || 4000),
persistent: !!event.detail.persistent
});
"
@mouseenter="toastsHovered=true;"
@mouseleave="toastsHovered=false"
x-init="
if(layout == 'expanded'){
expanded = true;
}
stackToasts();
$watch('toastsHovered', function(value){
if(layout == 'default'){
if(position.includes('bottom')){
resetBottom();
} else {
resetTop();
}
if(value){
// calculate the new positions
expanded = true;
if(layout == 'default'){
stackToasts();
}
} else {
if(layout == 'default'){
expanded = false;
setTimeout(function(){
stackToasts();
}, 10)
}
}
}
});
"
class="fixed block w-full group z-99 sm:max-w-lg"
:class="{ 'right-0 top-0 sm:mt-6 sm:mr-6': position=='top-right', 'left-0 top-0 sm:mt-6 sm:ml-6': position=='top-left', 'left-1/2 -translate-x-1/2 top-0 sm:mt-6': position=='top-center', 'right-0 top-0 sm:mr-6 sm:mb-6': position=='bottom-right', 'left-0 bottom-0 sm:ml-6 sm:mb-6': position=='bottom-left', 'left-0 bottom-0 sm:ml-6 sm:mb-6': position=='bottom-center' }"
x-cloak>
-